1. Home
  2. REAL vs ENGN Comparison

REAL vs ENGN Comparison

Compare REAL & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The RealReal Inc.

REAL

The RealReal Inc.

HOLD

Current Price

$9.20

Market Cap

1.1B

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.67

Market Cap

115.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
REAL
ENGN
Founded
2011
1999
Country
United States
Canada
Employees
N/A
82
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
115.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
REAL
ENGN
Price
$9.20
$1.67
Analyst Decision
Buy
Buy
Analyst Count
8
6
Target Price
$17.00
$21.08
AVG Volume (30 Days)
3.9M
3.2M
Earning Date
05-07-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
43.55
N/A
EPS
N/A
N/A
Revenue
$692,845,000.00
N/A
Revenue This Year
$14.30
N/A
Revenue Next Year
$10.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.38
N/A
52 Week Low
$4.71
$1.40
52 Week High
$17.39
$12.25

Technical Indicators

Market Signals
Indicator
REAL
ENGN
Relative Strength Index (RSI) 38.92 26.94
Support Level $8.05 $1.40
Resistance Level $11.48 $9.16
Average True Range (ATR) 0.69 0.28
MACD -0.21 -0.13
Stochastic Oscillator 10.64 3.49

Price Performance

Historical Comparison
REAL
ENGN

About REAL The RealReal Inc.

The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: